Fenwick & West represented AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, in its underwritten initial public offering of 5,750,000 shares of its common stock (inclusive of the underwriters’ option to purchase additional shares) at a price to the public of $15.00 per share.
Credit Suisse and Stifel acted as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow acted as co-managers.
The Fenwick transaction team included corporate partners Matthew Rossiter, Effie Toshav, Robert Freedman and Scott Spector and associates Elizabeth Gartland, Melissa Frayer, Ryan McRobert and Hans Andersson.